Industry
Medical - Diagnostics & Research
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Loading...
Open
8.54
Mkt cap
283M
Volume
58K
High
8.88
P/E Ratio
-8.71
52-wk high
12.36
Low
8.49
Div yield
N/A
52-wk low
4.52
Portfolio Pulse from
November 15, 2024 | 1:45 pm
Portfolio Pulse from
November 07, 2024 | 3:00 pm
Portfolio Pulse from
November 07, 2024 | 12:15 am
Portfolio Pulse from Chris Katje
November 01, 2024 | 7:16 pm
Portfolio Pulse from Benzinga Insights
October 14, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:44 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 12:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.